Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2012-06-02

AUTHORS

Gary K. Schwartz, Richard D. Carvajal, Rachel Midgley, Scott J. Rodig, Paul K. Stockman, Ozlem Ataman, David Wilson, Shampa Das, Geoffrey I. Shapiro

ABSTRACT

The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and safety profile for two different dosing regimens of barasertib, a selective inhibitor of Aurora B Kinase. In this Phase I trial, patients with advanced solid malignancies were treated with escalating doses of barasertib, administered as either a 48-h continuous infusion or as two 2-h infusions on consecutive days, both every 14 days of a 28-day cycle. Thirty-five patients were treated. The MTDs were 150 mg as a 48-h continuous infusion and 220 mg administered as two 2-h infusions (110 mg/day, days 1, 2, 15 and 16), with neutropenia the dose-limiting toxicity (DLT) of each schedule. Common Terminology Criteria of Adverse Events (CTCAE) grade ≥ 3 neutropenia (with or without fever) occurred in 34 % of patients overall. Other adverse events, many of hematologic or gastrointestinal etiology, were of mild or moderate intensity. No objective tumor responses were observed, although stable disease was observed in 23 % of patients. Systemic exposure to barasertib-hQPA, the more active moiety to which barasertib is converted, was observed by 1 and 6 h into the 2-h and continuous infusion, respectively, and exhibited linear pharmacokinetics. In summary, barasertib was generally well tolerated, with neutropenia the most frequent and dose-limiting toxicity, irrespective of schedule. Future development of barasertib will depend on better definition of its therapeutic index. More... »

PAGES

370-380

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10637-012-9825-7

DOI

http://dx.doi.org/10.1007/s10637-012-9825-7

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1035928416

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/22661287


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged, 80 and over", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aurora Kinase B", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aurora Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cohort Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Dose-Response Relationship, Drug", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Immunoenzyme Techniques", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Infusions, Intravenous", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Maximum Tolerated Dose", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Organophosphates", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prognosis", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Protein Serine-Threonine Kinases", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Quinazolines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tissue Distribution", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Schwartz", 
        "givenName": "Gary K.", 
        "id": "sg:person.012707142152.08", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012707142152.08"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA", 
          "id": "http://www.grid.ac/institutes/grid.51462.34", 
          "name": [
            "Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Carvajal", 
        "givenName": "Richard D.", 
        "id": "sg:person.0726366600.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Oncology, University of Oxford, Oxford, United Kingdom", 
          "id": "http://www.grid.ac/institutes/grid.4991.5", 
          "name": [
            "Department of Oncology, University of Oxford, Oxford, United Kingdom"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Midgley", 
        "givenName": "Rachel", 
        "id": "sg:person.0710471434.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710471434.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Pathology, Brigham and Women\u2019s Hospital, 75 Francis Street, 02115, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.62560.37", 
          "name": [
            "Department of Pathology, Brigham and Women\u2019s Hospital, 75 Francis Street, 02115, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Rodig", 
        "givenName": "Scott J.", 
        "id": "sg:person.01317104717.17", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317104717.17"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Stockman", 
        "givenName": "Paul K.", 
        "id": "sg:person.0605710446.44", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605710446.44"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ataman", 
        "givenName": "Ozlem", 
        "id": "sg:person.0745116571.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745116571.33"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Wilson", 
        "givenName": "David", 
        "id": "sg:person.01141045162.58", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141045162.58"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom", 
          "id": "http://www.grid.ac/institutes/grid.417815.e", 
          "name": [
            "AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Das", 
        "givenName": "Shampa", 
        "id": "sg:person.0627122107.30", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627122107.30"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, 02215, Boston, MA, USA", 
          "id": "http://www.grid.ac/institutes/grid.65499.37", 
          "name": [
            "Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, 02215, Boston, MA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shapiro", 
        "givenName": "Geoffrey I.", 
        "id": "sg:person.0752005421.01", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752005421.01"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1038/sj.bjc.6602779", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1040849298", 
          "https://doi.org/10.1038/sj.bjc.6602779"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/sj.onc.1208752", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1026873161", 
          "https://doi.org/10.1038/sj.onc.1208752"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s10555-009-9184-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012258889", 
          "https://doi.org/10.1007/s10555-009-9184-9"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrc1502", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007682820", 
          "https://doi.org/10.1038/nrc1502"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrm1245", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1049953107", 
          "https://doi.org/10.1038/nrm1245"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/bjc.2011.21", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028516879", 
          "https://doi.org/10.1038/bjc.2011.21"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/nrm2257", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1011203730", 
          "https://doi.org/10.1038/nrm2257"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-010-1318-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1015138321", 
          "https://doi.org/10.1007/s00280-010-1318-9"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2012-06-02", 
    "datePublishedReg": "2012-06-02", 
    "description": "The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and safety profile for two different dosing regimens of barasertib, a selective inhibitor of Aurora B Kinase. In this Phase I trial, patients with advanced solid malignancies were treated with escalating doses of barasertib, administered as either a 48-h continuous infusion or as two 2-h infusions on consecutive days, both every 14\u00a0days of a 28-day cycle. Thirty-five patients were treated. The MTDs were 150\u00a0mg as a 48-h continuous infusion and 220\u00a0mg administered as two 2-h infusions (110\u00a0mg/day, days 1, 2, 15 and 16), with neutropenia the dose-limiting toxicity (DLT) of each schedule. Common Terminology Criteria of Adverse Events (CTCAE) grade\u2009\u2265\u20093 neutropenia (with or without fever) occurred in 34\u00a0% of patients overall. Other adverse events, many of hematologic or gastrointestinal etiology, were of mild or moderate intensity. No objective tumor responses were observed, although stable disease was observed in 23\u00a0% of patients. Systemic exposure to barasertib-hQPA, the more active moiety to which barasertib is converted, was observed by 1 and 6\u00a0h into the 2-h and continuous infusion, respectively, and exhibited linear pharmacokinetics. In summary, barasertib was generally well tolerated, with neutropenia the most frequent and dose-limiting toxicity, irrespective of schedule. Future development of barasertib will depend on better definition of its therapeutic index.", 
    "genre": "article", 
    "id": "sg:pub.10.1007/s10637-012-9825-7", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "publisher": "Springer Nature", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "2", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "maximum-tolerated dose", 
      "dose-limiting toxicity", 
      "continuous infusion", 
      "Common Terminology Criteria", 
      "adverse events grade", 
      "advanced solid malignancies", 
      "objective tumor response", 
      "advanced solid tumors", 
      "phase I trial", 
      "selective inhibitor", 
      "Terminology Criteria", 
      "stable disease", 
      "barasertib-hQPA", 
      "adverse events", 
      "I trial", 
      "gastrointestinal etiology", 
      "safety profile", 
      "systemic exposure", 
      "tumor response", 
      "linear pharmacokinetics", 
      "solid malignancies", 
      "events grade", 
      "therapeutic index", 
      "patients", 
      "solid tumors", 
      "barasertib", 
      "infusion", 
      "neutropenia", 
      "consecutive days", 
      "phase I", 
      "moderate intensity", 
      "pharmacokinetics", 
      "active moiety", 
      "inhibitors", 
      "better definition", 
      "toxicity", 
      "B kinase", 
      "days", 
      "regimens", 
      "malignancy", 
      "etiology", 
      "tumors", 
      "disease", 
      "dose", 
      "doses", 
      "trials", 
      "kinase", 
      "schedule", 
      "exposure", 
      "grade", 
      "response", 
      "index", 
      "criteria", 
      "summary", 
      "study", 
      "Aurora B kinase", 
      "events", 
      "profile", 
      "purpose", 
      "future development", 
      "development", 
      "cycle", 
      "definition", 
      "intensity", 
      "moiety"
    ], 
    "name": "Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors", 
    "pagination": "370-380", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1035928416"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10637-012-9825-7"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "22661287"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10637-012-9825-7", 
      "https://app.dimensions.ai/details/publication/pub.1035928416"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-12-01T06:30", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221201/entities/gbq_results/article/article_572.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1007/s10637-012-9825-7"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9825-7'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9825-7'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9825-7'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10637-012-9825-7'


 

This table displays all metadata directly associated to this object as RDF triples.

310 TRIPLES      21 PREDICATES      119 URIs      103 LITERALS      28 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10637-012-9825-7 schema:about N062585048d274642a9a8dc7e16826fc4
2 N0c3d5376a5cb4f9eb91091992a98d670
3 N1372409f0e3b485687923e89d8ed50be
4 N16ca3ffa306d43cf83dca8cb9508bb75
5 N1f8862353ad049fd84a6190e932c0e0f
6 N274c2c6844024459a19bee68e52dde62
7 N296fe9a6042e4a39b1e5380c90f955e0
8 N2e1801de3979456bb71371db2a68ad5a
9 N30b208ecb6d74e5fb893f103c71c7721
10 N484a8159c3d043a2a9ea2d37f656a3e8
11 N4fed661d0b684814a8376c40954efc50
12 N7cb10f825bd7414eaeee376f5daed76f
13 N92530d7882a54b1e979b1c103af9ea54
14 N9394460542ec48a9b0cf4a5c72231a93
15 N98818184ff6644299fc4043fe352e10e
16 Nb2549ffa3c094c1dafc7f0a1095f1034
17 Nc9f93c8b3e164c0aa9b881943049e602
18 Ne74351af87fc4edda4ec6d99e34caca5
19 Ne7839f9d008249059ee55966884c8735
20 Nf82b55494b964c7781701d9ccd38bc4b
21 Nfe8ab4e650bf4740bfd90bad1ba52931
22 anzsrc-for:11
23 anzsrc-for:1103
24 schema:author N90342bece87c4ad5a907e42e03ebbd4e
25 schema:citation sg:pub.10.1007/s00280-010-1318-9
26 sg:pub.10.1007/s10555-009-9184-9
27 sg:pub.10.1038/bjc.2011.21
28 sg:pub.10.1038/nrc1502
29 sg:pub.10.1038/nrm1245
30 sg:pub.10.1038/nrm2257
31 sg:pub.10.1038/sj.bjc.6602779
32 sg:pub.10.1038/sj.onc.1208752
33 schema:datePublished 2012-06-02
34 schema:datePublishedReg 2012-06-02
35 schema:description The purpose of this study was to determine the maximum-tolerated dose (MTD), pharmacokinetics and safety profile for two different dosing regimens of barasertib, a selective inhibitor of Aurora B Kinase. In this Phase I trial, patients with advanced solid malignancies were treated with escalating doses of barasertib, administered as either a 48-h continuous infusion or as two 2-h infusions on consecutive days, both every 14 days of a 28-day cycle. Thirty-five patients were treated. The MTDs were 150 mg as a 48-h continuous infusion and 220 mg administered as two 2-h infusions (110 mg/day, days 1, 2, 15 and 16), with neutropenia the dose-limiting toxicity (DLT) of each schedule. Common Terminology Criteria of Adverse Events (CTCAE) grade ≥ 3 neutropenia (with or without fever) occurred in 34 % of patients overall. Other adverse events, many of hematologic or gastrointestinal etiology, were of mild or moderate intensity. No objective tumor responses were observed, although stable disease was observed in 23 % of patients. Systemic exposure to barasertib-hQPA, the more active moiety to which barasertib is converted, was observed by 1 and 6 h into the 2-h and continuous infusion, respectively, and exhibited linear pharmacokinetics. In summary, barasertib was generally well tolerated, with neutropenia the most frequent and dose-limiting toxicity, irrespective of schedule. Future development of barasertib will depend on better definition of its therapeutic index.
36 schema:genre article
37 schema:isAccessibleForFree false
38 schema:isPartOf N7b56a150f6d748d7bd34e931b0298355
39 Necf285bd85c244bdb749ad0457fe27bc
40 sg:journal.1094201
41 schema:keywords Aurora B kinase
42 B kinase
43 Common Terminology Criteria
44 I trial
45 Terminology Criteria
46 active moiety
47 advanced solid malignancies
48 advanced solid tumors
49 adverse events
50 adverse events grade
51 barasertib
52 barasertib-hQPA
53 better definition
54 consecutive days
55 continuous infusion
56 criteria
57 cycle
58 days
59 definition
60 development
61 disease
62 dose
63 dose-limiting toxicity
64 doses
65 etiology
66 events
67 events grade
68 exposure
69 future development
70 gastrointestinal etiology
71 grade
72 index
73 infusion
74 inhibitors
75 intensity
76 kinase
77 linear pharmacokinetics
78 malignancy
79 maximum-tolerated dose
80 moderate intensity
81 moiety
82 neutropenia
83 objective tumor response
84 patients
85 pharmacokinetics
86 phase I
87 phase I trial
88 profile
89 purpose
90 regimens
91 response
92 safety profile
93 schedule
94 selective inhibitor
95 solid malignancies
96 solid tumors
97 stable disease
98 study
99 summary
100 systemic exposure
101 therapeutic index
102 toxicity
103 trials
104 tumor response
105 tumors
106 schema:name Phase I study of barasertib (AZD1152), a selective inhibitor of Aurora B kinase, in patients with advanced solid tumors
107 schema:pagination 370-380
108 schema:productId N68f6b40ab76144aeb9b52d3bf68792b4
109 N854bf92630c8458880d47264ecf9018f
110 Nb4941686bcd34235bad4f4d3ace80151
111 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035928416
112 https://doi.org/10.1007/s10637-012-9825-7
113 schema:sdDatePublished 2022-12-01T06:30
114 schema:sdLicense https://scigraph.springernature.com/explorer/license/
115 schema:sdPublisher Nda89fc09c6f143b6865fd79d178d1e1a
116 schema:url https://doi.org/10.1007/s10637-012-9825-7
117 sgo:license sg:explorer/license/
118 sgo:sdDataset articles
119 rdf:type schema:ScholarlyArticle
120 N062585048d274642a9a8dc7e16826fc4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
121 schema:name Organophosphates
122 rdf:type schema:DefinedTerm
123 N0c3d5376a5cb4f9eb91091992a98d670 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
124 schema:name Cohort Studies
125 rdf:type schema:DefinedTerm
126 N0dfb125a8d3b46b49b3a6ec2ceb24b63 rdf:first sg:person.0710471434.44
127 rdf:rest Nf22dfb8b7a594af38757365fa7f041c0
128 N1372409f0e3b485687923e89d8ed50be schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Maximum Tolerated Dose
130 rdf:type schema:DefinedTerm
131 N16ca3ffa306d43cf83dca8cb9508bb75 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Quinazolines
133 rdf:type schema:DefinedTerm
134 N1f8862353ad049fd84a6190e932c0e0f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Adult
136 rdf:type schema:DefinedTerm
137 N208b46e1091344528f457f6e25077127 rdf:first sg:person.0752005421.01
138 rdf:rest rdf:nil
139 N274c2c6844024459a19bee68e52dde62 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Follow-Up Studies
141 rdf:type schema:DefinedTerm
142 N296fe9a6042e4a39b1e5380c90f955e0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
143 schema:name Prognosis
144 rdf:type schema:DefinedTerm
145 N2e1801de3979456bb71371db2a68ad5a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
146 schema:name Aged
147 rdf:type schema:DefinedTerm
148 N30b208ecb6d74e5fb893f103c71c7721 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Aurora Kinases
150 rdf:type schema:DefinedTerm
151 N35d06d30e97b4dc58d979fae60f95889 rdf:first sg:person.01141045162.58
152 rdf:rest Nb03b840cced04196a8500ce87ad11a3e
153 N3c3ca0cb9eb54f9d93c1550a9403b93c rdf:first sg:person.0726366600.25
154 rdf:rest N0dfb125a8d3b46b49b3a6ec2ceb24b63
155 N484a8159c3d043a2a9ea2d37f656a3e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
156 schema:name Humans
157 rdf:type schema:DefinedTerm
158 N4fed661d0b684814a8376c40954efc50 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
159 schema:name Immunoenzyme Techniques
160 rdf:type schema:DefinedTerm
161 N68f6b40ab76144aeb9b52d3bf68792b4 schema:name pubmed_id
162 schema:value 22661287
163 rdf:type schema:PropertyValue
164 N7b56a150f6d748d7bd34e931b0298355 schema:volumeNumber 31
165 rdf:type schema:PublicationVolume
166 N7cb10f825bd7414eaeee376f5daed76f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
167 schema:name Middle Aged
168 rdf:type schema:DefinedTerm
169 N854bf92630c8458880d47264ecf9018f schema:name doi
170 schema:value 10.1007/s10637-012-9825-7
171 rdf:type schema:PropertyValue
172 N90342bece87c4ad5a907e42e03ebbd4e rdf:first sg:person.012707142152.08
173 rdf:rest N3c3ca0cb9eb54f9d93c1550a9403b93c
174 N92530d7882a54b1e979b1c103af9ea54 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
175 schema:name Tissue Distribution
176 rdf:type schema:DefinedTerm
177 N9394460542ec48a9b0cf4a5c72231a93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
178 schema:name Aged, 80 and over
179 rdf:type schema:DefinedTerm
180 N98818184ff6644299fc4043fe352e10e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
181 schema:name Dose-Response Relationship, Drug
182 rdf:type schema:DefinedTerm
183 N9fdf931d8fa14cf391cedecbc1c26a17 rdf:first sg:person.0605710446.44
184 rdf:rest Neab3ce306d534cafae38e288f442a653
185 Nb03b840cced04196a8500ce87ad11a3e rdf:first sg:person.0627122107.30
186 rdf:rest N208b46e1091344528f457f6e25077127
187 Nb2549ffa3c094c1dafc7f0a1095f1034 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
188 schema:name Aurora Kinase B
189 rdf:type schema:DefinedTerm
190 Nb4941686bcd34235bad4f4d3ace80151 schema:name dimensions_id
191 schema:value pub.1035928416
192 rdf:type schema:PropertyValue
193 Nc9f93c8b3e164c0aa9b881943049e602 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
194 schema:name Neoplasms
195 rdf:type schema:DefinedTerm
196 Nda89fc09c6f143b6865fd79d178d1e1a schema:name Springer Nature - SN SciGraph project
197 rdf:type schema:Organization
198 Ne74351af87fc4edda4ec6d99e34caca5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Infusions, Intravenous
200 rdf:type schema:DefinedTerm
201 Ne7839f9d008249059ee55966884c8735 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Male
203 rdf:type schema:DefinedTerm
204 Neab3ce306d534cafae38e288f442a653 rdf:first sg:person.0745116571.33
205 rdf:rest N35d06d30e97b4dc58d979fae60f95889
206 Necf285bd85c244bdb749ad0457fe27bc schema:issueNumber 2
207 rdf:type schema:PublicationIssue
208 Nf22dfb8b7a594af38757365fa7f041c0 rdf:first sg:person.01317104717.17
209 rdf:rest N9fdf931d8fa14cf391cedecbc1c26a17
210 Nf82b55494b964c7781701d9ccd38bc4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
211 schema:name Protein Serine-Threonine Kinases
212 rdf:type schema:DefinedTerm
213 Nfe8ab4e650bf4740bfd90bad1ba52931 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
214 schema:name Female
215 rdf:type schema:DefinedTerm
216 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
217 schema:name Medical and Health Sciences
218 rdf:type schema:DefinedTerm
219 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
220 schema:name Clinical Sciences
221 rdf:type schema:DefinedTerm
222 sg:journal.1094201 schema:issn 0167-6997
223 1573-0646
224 schema:name Investigational New Drugs
225 schema:publisher Springer Nature
226 rdf:type schema:Periodical
227 sg:person.01141045162.58 schema:affiliation grid-institutes:grid.417815.e
228 schema:familyName Wilson
229 schema:givenName David
230 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141045162.58
231 rdf:type schema:Person
232 sg:person.012707142152.08 schema:affiliation grid-institutes:grid.51462.34
233 schema:familyName Schwartz
234 schema:givenName Gary K.
235 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012707142152.08
236 rdf:type schema:Person
237 sg:person.01317104717.17 schema:affiliation grid-institutes:grid.62560.37
238 schema:familyName Rodig
239 schema:givenName Scott J.
240 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01317104717.17
241 rdf:type schema:Person
242 sg:person.0605710446.44 schema:affiliation grid-institutes:grid.417815.e
243 schema:familyName Stockman
244 schema:givenName Paul K.
245 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0605710446.44
246 rdf:type schema:Person
247 sg:person.0627122107.30 schema:affiliation grid-institutes:grid.417815.e
248 schema:familyName Das
249 schema:givenName Shampa
250 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0627122107.30
251 rdf:type schema:Person
252 sg:person.0710471434.44 schema:affiliation grid-institutes:grid.4991.5
253 schema:familyName Midgley
254 schema:givenName Rachel
255 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0710471434.44
256 rdf:type schema:Person
257 sg:person.0726366600.25 schema:affiliation grid-institutes:grid.51462.34
258 schema:familyName Carvajal
259 schema:givenName Richard D.
260 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0726366600.25
261 rdf:type schema:Person
262 sg:person.0745116571.33 schema:affiliation grid-institutes:grid.417815.e
263 schema:familyName Ataman
264 schema:givenName Ozlem
265 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0745116571.33
266 rdf:type schema:Person
267 sg:person.0752005421.01 schema:affiliation grid-institutes:grid.65499.37
268 schema:familyName Shapiro
269 schema:givenName Geoffrey I.
270 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752005421.01
271 rdf:type schema:Person
272 sg:pub.10.1007/s00280-010-1318-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1015138321
273 https://doi.org/10.1007/s00280-010-1318-9
274 rdf:type schema:CreativeWork
275 sg:pub.10.1007/s10555-009-9184-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012258889
276 https://doi.org/10.1007/s10555-009-9184-9
277 rdf:type schema:CreativeWork
278 sg:pub.10.1038/bjc.2011.21 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028516879
279 https://doi.org/10.1038/bjc.2011.21
280 rdf:type schema:CreativeWork
281 sg:pub.10.1038/nrc1502 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007682820
282 https://doi.org/10.1038/nrc1502
283 rdf:type schema:CreativeWork
284 sg:pub.10.1038/nrm1245 schema:sameAs https://app.dimensions.ai/details/publication/pub.1049953107
285 https://doi.org/10.1038/nrm1245
286 rdf:type schema:CreativeWork
287 sg:pub.10.1038/nrm2257 schema:sameAs https://app.dimensions.ai/details/publication/pub.1011203730
288 https://doi.org/10.1038/nrm2257
289 rdf:type schema:CreativeWork
290 sg:pub.10.1038/sj.bjc.6602779 schema:sameAs https://app.dimensions.ai/details/publication/pub.1040849298
291 https://doi.org/10.1038/sj.bjc.6602779
292 rdf:type schema:CreativeWork
293 sg:pub.10.1038/sj.onc.1208752 schema:sameAs https://app.dimensions.ai/details/publication/pub.1026873161
294 https://doi.org/10.1038/sj.onc.1208752
295 rdf:type schema:CreativeWork
296 grid-institutes:grid.417815.e schema:alternateName AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom
297 schema:name AstraZeneca Pharmaceuticals, Macclesfield, Cheshire, United Kingdom
298 rdf:type schema:Organization
299 grid-institutes:grid.4991.5 schema:alternateName Department of Oncology, University of Oxford, Oxford, United Kingdom
300 schema:name Department of Oncology, University of Oxford, Oxford, United Kingdom
301 rdf:type schema:Organization
302 grid-institutes:grid.51462.34 schema:alternateName Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
303 schema:name Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY, USA
304 rdf:type schema:Organization
305 grid-institutes:grid.62560.37 schema:alternateName Department of Pathology, Brigham and Women’s Hospital, 75 Francis Street, 02115, Boston, MA, USA
306 schema:name Department of Pathology, Brigham and Women’s Hospital, 75 Francis Street, 02115, Boston, MA, USA
307 rdf:type schema:Organization
308 grid-institutes:grid.65499.37 schema:alternateName Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, 02215, Boston, MA, USA
309 schema:name Early Drug Development Center, Department of Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, 02215, Boston, MA, USA
310 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...